Alcohol-use disorder, addiction and Awakn’s expansion across the Atlantic
Awakn Life Sciences announced that its Phase III clinical trial with ketamine-assisted therapy for the treatment of alcohol-use disorder would be delivered across seven NHS sites in the UK.
Furthermore, two-thirds of the study will be funded by UK government agencies, in recognition of the treatment’s potential efficacy and its socioeconomic impact. It is estimated over two million UK adults have serious alcohol problems, but only one in five receive treatment.
To discuss alcohol-use disorder, addiction and Awakn’s expansion across the Atlantic, PSYCH spoke with Kevin Lorenz, US Head of Commercial Development.READ MORE